Goldman Sachs’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Goldman Sachs’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$457K	Buy	+8,674	New	+$387K	﹤0.01%	5752
2023 Q1	–	Sell	-100,000	Closed	-$2.5M	–	5914
2022 Q4	$2.5M	Hold	100,000	–	–	﹤0.01%	3763
2022 Q3	$2.46M	Hold	100,000	–	–	﹤0.01%	3801
2022 Q2	$2.16M	Hold	100,000	–	–	﹤0.01%	3980
2022 Q1	$2.79M	Hold	100,000	–	–	﹤0.01%	3932
2021 Q4	$3.85M	Hold	100,000	–	–	﹤0.01%	3670
2021 Q3	$4.57M	Hold	100,000	–	–	﹤0.01%	3438
2021 Q2	$4.99M	Hold	100,000	–	–	﹤0.01%	3338
2021 Q1	$5.14M	Hold	100,000	–	–	﹤0.01%	3113
2020 Q4	$4.96M	Hold	100,000	–	–	﹤0.01%	3006
2020 Q3	$3.9M	Hold	100,000	–	–	﹤0.01%	3085
2020 Q2	$4.32M	Hold	100,000	–	–	﹤0.01%	2912
2020 Q1	$2.93M	Hold	100,000	–	–	﹤0.01%	3039
2019 Q4	$3.81M	Hold	100,000	–	–	﹤0.01%	3176
2019 Q3	$2.38M	Hold	100,000	–	–	﹤0.01%	3423
2019 Q2	$2.88M	Hold	100,000	–	–	﹤0.01%	3270
2019 Q1	$2.85M	Hold	100,000	–	–	﹤0.01%	3371
2018 Q4	$2.32M	Hold	100,000	–	–	﹤0.01%	3436
2018 Q3	$3.46M	Hold	100,000	–	–	﹤0.01%	3240
2018 Q2	$3.27M	Hold	100,000	–	–	﹤0.01%	3262
2018 Q1	$3.28M	Sell	100,000 -1,888	-2%	-$61.6K	﹤0.01%	3229
2017 Q4	$2.9M	Sell	101,888 -8,534	-8%	-$239K	﹤0.01%	3481
2017 Q3	$3.22M	Sell	110,422 -1,300	-1%	-$33.6K	﹤0.01%	3549
2017 Q2	$2.68M	Sell	111,722 -2,300	-2%	-$51.5K	﹤0.01%	3590
2017 Q1	$2.64M	Sell	114,022 -2,223	-2%	-$47.3K	﹤0.01%	3473
2016 Q4	$2.14M	Buy	116,245 +16,245	+16%	+$324K	﹤0.01%	3791
2016 Q3	$2.27M	Hold	100,000	–	–	﹤0.01%	3714
2016 Q2	$1.8M	Hold	100,000	–	–	﹤0.01%	3715
2016 Q1	$1.91M	Hold	100,000	–	–	﹤0.01%	3516
2015 Q4	$2.9M	Hold	100,000	–	–	﹤0.01%	3311
2015 Q3	$2.64M	Hold	100,000	–	–	﹤0.01%	3505
2015 Q2	$3.62M	Sell	100,000 -100,000	-50%	-$3.44M	﹤0.01%	3250
2015 Q1	$6.57M	Buy	+200,000	New	+$6.11M	﹤0.01%	2650

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Goldman Sachs's BBC Position: Q2 2026 in Review

Goldman Sachs opened a new position in Virtus Biotech Clinical Trials ETF (BBC) in Q2 2026: 8,674 shares worth $457K. The stake represents ﹤0.01% of the portfolio and ranks #5752 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in BBC as recently as Q4 2022.

Goldman Sachs first reported a position in BBC in Q1 2015 and has held it in 33 quarters since. The position peaked at $6.57M in Q1 2015. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

Goldman Sachs held 8,674 shares of Virtus Biotech Clinical Trials ETF worth $457K as of Q2 2026.
Virtus Biotech Clinical Trials ETF was a new Goldman Sachs position in Q2 2026.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5752 holding.
Goldman Sachs first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2015 and has held it in 33 quarters since.
Goldman Sachs's Virtus Biotech Clinical Trials ETF position peaked at $6.57M in Q1 2015.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.